Patents by Inventor John C. Hartnett

John C. Hartnett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRPA1 antagonists
    Patent number: 8829196
    Abstract: The present invention relates to compositions and methods that modulate at least one TRP family member. Specifically, the present invention relates to novel TRPA1 antagonists and their use in the treatment of pain such as chronic inflammatory and neuropathic pain. Compounds that can modulate one or more TRPA1 functions are useful in many aspects including, but not limited to, maintaining calcium homeostasis; maintaining sodium homeostasis; modulating intracellular calcium levels; modulating membrane polarization (membrane potential); modulating cation levels; and/or treating or preventing diseases, disorders, or conditions associated with calcium homeostasis, sodium homeostasis, calcium or sodium dyshomeostasis, or membrane polarization/hyperpolarization (including hypo and hyperexcitability), and/or treating or preventing diseases, disorders, or conditions associated with regulation or misregulation of TRPA1 expression or function.
    Type: Grant
    Filed: September 28, 2010
    Date of Patent: September 9, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Mark T. Bilodeau, Melissa Egbertson, Ahren Green, John C. Hartnett, Yiwei Li
  • Quinolone neuropeptide S receptor antagonists
    Patent number: 8389720
    Abstract: The present invention is directed to quinolone compounds which are antagonists of neuropeptide S receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which the neuropeptide S receptor is involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the neuropeptide S receptor is involved.
    Type: Grant
    Filed: November 3, 2009
    Date of Patent: March 5, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: James C. Barrow, Mark T. Bilodeau, Christopher D. Cox, John C. Hartnett, Nathan R. Kett, Yiwei Li, Peter J. Manley, Jeffrey Melamed, William D. Shipe, B. Wesley Trotter, Amy Zartman
  • NOVEL TRPA1 ANTAGONISTS
    Publication number: 20120196894
    Abstract: The present invention relates to compositions and methods that modulate at least one TRP family member. Specifically, the present invention relates to novel TRPA1 antagonists and their use in the treatment of pain such as chronic inflammatory and neuropathic pain. Compounds that can modulate one or more TRPA1 functions are useful in many aspects including, but not limited to, maintaining calcium homeostasis; maintaining sodium homeostasis; modulating intracellular calcium levels; modulating membrane polarization (membrane potential); modulating cation levels; and/or treating or preventing diseases, disorders, or conditions associated with calcium homeostasis, sodium homeostasis, calcium or sodium dyshomeostasis, or membrane polarization/hyperpolarization (including hypo and hyperexcitability), and/or treating or preventing diseases, disorders, or conditions associated with regulation or misregulation of TRPA1 expression or function.
    Type: Application
    Filed: September 28, 2010
    Publication date: August 2, 2012
    Inventors: Mark T. Bilodeau, Melissa Egbertson, Ahren Green, John C. Hartnett, Yiwei Li
  • Quinolone Neuropeptide S Receptor Antagonists
    Publication number: 20110212946
    Abstract: The present invention is directed to quinolone compounds which are antagonists of neuropeptide S receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which the neuropeptide S receptor is involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the neuropeptide S receptor is involved.
    Type: Application
    Filed: November 3, 2009
    Publication date: September 1, 2011
    Inventors: James C. Barrow, Mark T. Bilodeau, Christopher D. Cox, John C. Hartnett, Nathan R. Kett, Yiwei Li, Peter J. Manley, Jeffrey Melamed, William D. Shipe, B. Wesley Trotter, Amy Zartman
  • SUBSTITUTED 1,2,4-OXADIAZOLES AND ANALOGS THEREOF AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES
    Publication number: 20100227845
    Abstract: The present invention relates to compounds represented by Formula (I), Formula (II) and Formula (III) and pharmaceutically acceptable salts thereof. The present invention also provides pharmaceutical compositions comprising the instant compounds. This invention further provides methods to treat and prevent pain, respiratory and non-respiratory diseases.
    Type: Application
    Filed: October 14, 2008
    Publication date: September 9, 2010
    Inventors: Zhicai Wu, John C. Hartnett
  • Inhibitors of Akt activity
    Patent number: 7750151
    Abstract: The present invention is directed to compounds which contain substituted napthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.
    Type: Grant
    Filed: April 5, 2005
    Date of Patent: July 6, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Mark T. Bilodeau, Chixu Chen, Nicholas D. P. Cosford, Brian W. Eastman, John C. Hartnett, Essa H. Hu, Peter J. Manley, Lou Anne Neilson, Lida R. Tehrani, Zhicai Wu
  • IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES
    Publication number: 20090325936
    Abstract: The present invention relates to compounds represented by Formula (I) and Formula (II): (I) (II) or pharmaceutically acceptable salts thereof. The present invention also provides pharmaceutical compositions comprising the instant compounds. This invention further provides methods to treat and prevent pain, respiratory and non-respiratory diseases.
    Type: Application
    Filed: December 14, 2007
    Publication date: December 31, 2009
    Inventors: Mark T. Bilodeau, Christopher S. Burgey, Zhengwu James Deng, Nathan R. Kett, Jeffrey Melamed, Peter M. Munson, Kausik K. Nanda, Wayne Thompson, B. Wesley Trotter, Zhicai Wu, John C. Hartnett
  • Inhibitors of Akt activity
    Patent number: 7579355
    Abstract: The present invention is directed to compounds which contain a substituted pyridine moeity which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.
    Type: Grant
    Filed: April 20, 2004
    Date of Patent: August 25, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, Mark E. Duggan, John C. Hartnett, Craig W. Lindsley, Zhicai Wu, Zhijian Zhao
  • Inhibitors of Akt activity
    Patent number: 7544677
    Abstract: The present invention is directed to compounds which contain substituted 5-deazapteridine moieties which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.
    Type: Grant
    Filed: August 19, 2005
    Date of Patent: June 9, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, Nicholas D. P. Cosford, John C. Hartnett, Yiwei Li, Jun Liang, Peter J. Manley, Lou Anne Neilson, Tony Siu, Zhicai Wu
  • Inhibitors of Akt Activity
    Publication number: 20080280899
    Abstract: The present invention is directed to compounds which contain substituted napthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.
    Type: Application
    Filed: April 5, 2005
    Publication date: November 13, 2008
    Inventors: Mark T. Bilodeau, Chixu Chen, Nicholas D.P. Cosford, Brian W. Eastman, John C. Hartnett, Essa H. Hu, Peter J. Manley, Lou Anne Neilson, Lida R. Tehrani, Zhicai Wu
  • Inhibitors of Akt activity
    Patent number: 7414055
    Abstract: The present invention is directed to compounds which contain a substituted pyridine moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.
    Type: Grant
    Filed: April 20, 2004
    Date of Patent: August 19, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Mark E. Duggan, Craig W. Lindsley, Zhicai Wu, Zhijian Zhao, John C. Hartnett
  • Inhibitors of Akt activity
    Patent number: 7223738
    Abstract: The present invention is directed to compounds comprising a 2,3-diphenylquinoxaline moiety which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.
    Type: Grant
    Filed: April 4, 2003
    Date of Patent: May 29, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Mark T. Bilodeau, Mark E. Duggan, John C. Hartnett, Craig W. Lindsley, Peter J. Manley, Zhicai Wu, Zhijian Zhao